Alkem Laboratories IPO
Alkem Laboratories IPO — date, price band, lot size & details 2015
Alkem Laboratories listed on 23 Dec 2015 at ₹1,380, 31.4% above the ₹1,050 issue price.
Alkem Laboratories develops, makes and sells branded generics, generics, APIs and nutraceuticals in India and 55 countries, mainly the United States. Its total income was Rs 3,365.06 crore in FY2015.
Stock price
Alkem Laboratories is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 15 November.
- Open 08 Dec 2015
- Close 10 Dec 2015
- Allotment 15 Dec 2015
- Refund/credit TBA
- Listing 23 Dec 2015
Issue summary
The terms of the offer, as filed.
| IPO Dates | 8 to 10 Dec, 2015 |
|---|---|
| Price Band | ₹1020 – ₹1050 |
| Face Value | ₹2 |
| Lot Size | 14 Shares |
| Issue Size | ₹1347.76 Cr |
| Sale Type | OFS only |
| Listing On | BSE, NSE |
| Employee Discount | Rs 100.00 per share |
| Registrar | MUFG Intime India Private Limited |
| Min Investment | ₹ 14,700 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 14 shares at the ₹1050 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 14 | ₹14,700 |
| Retail (max) | 13 | 182 | ₹1,91,100 |
| S-HNI (min) | 14 | 196 | ₹2,05,800 |
| S-HNI (max) | 68 | 952 | ₹9,99,600 |
| B-HNI (min) | 69 | 966 | ₹10,14,300 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 4
- 01Total income rose from Rs 2,469.01 crore in FY2013 to Rs 3,365.06 crore in FY2015.
- 02Net worth rose from Rs 2,302.73 crore in FY2013 to Rs 3,468.70 crore on 30 September 2015.
- 03Total borrowing fell from Rs 1,186.03 crore in FY2013 to Rs 872.21 crore on 30 September 2015.
- 04It sells in India and 55 other countries.
Risks · 5
- 01Profit after tax slipped from Rs 466.78 crore in FY2013 to Rs 438.84 crore in FY2015.
- 02US generics face price erosion and FDA inspections; total assets were Rs 5,118.18 crore.
- 03Indian drug price controls can limit pricing of its branded generics; profit was Rs 414.74 crore in six months to September 2015.
- 04The whole Rs 1,347.76 crore issue was an offer for sale, so none of it went to the company.
- 05Promoters held 70.87% before the issue and 66.23% after it.
Three years of numbers
All figures in ₹ crore, as reported in the Alkem Laboratories offer document.
| Metric | 30 Sep 2015 | 31 Mar 2015 | 31 Mar 2014 | 31 Mar 2013 |
|---|---|---|---|---|
| Assets | 5,118.18 | 4,866.34 | 4,201.56 | 4,011.22 |
| Total Income | 2,146.94 | 3,365.06 | 2,839.58 | 2,469.01 |
| Profit After Tax | 414.74 | 438.84 | 440.20 | 466.78 |
| NET Worth | 3,468.70 | 3,097.13 | 2,714.95 | 2,302.73 |
| Reserves and Surplus | 3,444.79 | 3,073.22 | 2,703.00 | 2,290.78 |
| Total Borrowing | 872.21 | 1,074.41 | 899.14 | 1,186.03 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Alkem Laboratories RHP.
Where the money goes
How the company intends to use the proceeds of the issue.
Information about the usage of proceeds from the Alkem Laboratories IPO will be updated shortly.
Alkem Laboratories IPO Anchor Investors
47 anchor investors across 17 fund houses committed ₹395.52 Cr a day before the issue opened.
Anchor investors bid a day before the issue opens and are locked in after allotment, so a book weighted towards domestic mutual funds is generally read as a stronger signal than one filled by short-horizon funds. Browse every anchor investor scheme or fund house we track.
About the company
It develops, makes and sells pharmaceutical and nutraceutical products, including branded generics, generic drugs, active pharmaceutical ingredients and nutraceuticals.
It markets its products in India and in 55 countries internationally, mainly the United States, through domestic and international businesses.
The IPO was Rs 1,347.76 crore and was entirely an offer for sale at Rs 1,050, the top of the Rs 1,020 to Rs 1,050 band, so the company received no money.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Alkem Laboratories IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Axis Capital
256 issues handledBest listing: Latent View Analytics (+160.0%). Weakest: Shriram Properties (-23.7%).
JP Morgan India Pvt. Ltd
41 issues handledBest listing: Premier Energies (+120.0%). Weakest: Nuvoco Vistas Corporation (-14.9%).
Nomura Financial Advisory & Securities (India) Pvt. Ltd
37 issues handledBest listing: Happiest Minds Technologies (+110.8%). Weakest: Shriram Properties (-23.7%).
Edelweiss Financial Services Ltd
73 issues handledBest listing: Route Mobile (+104.9%). Weakest: ICICI Securities (-16.3%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Alkem Laboratories?
The current Grey Market Premium is ₹0.
What is the Alkem Laboratories IPO price band?
₹1020 to ₹1050, on a face value of ₹2.
When is the allotment?
The basis of allotment is 15 December 2015, with listing on 23 December 2015.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
